Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

White Matter Changes May Predict Dementia Risk
Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

Compugen Announces Positive Therapeutic Effects Of Novel Peptide In Animal Model Of Inflammatory Bowel Disease
Compugen Ltd. (NASDAQ:CGEN) announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn"s disease.
News of the day
FDA Approves SAMSCA(TM) (tolvaptan), The First And Only Oral Vasopressin Antagonist To Treat Patients With Clinically Significant Hypervolemic
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be treated with SAMSCA. Additionally, it has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. SAMSCA, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc. (OAPI).
Oncology

Researchers Develop An Intelligent Chip Which Regulates Diabetes

Scientists of the Electronic Technology group of the University of Seville (US), led by Professor José Manuel Quero, have completed the first phase of Mireia, a research project financed by the Plan Nacional del Ministerio de Ciencia e InnovaciÃön (National Plan of the Spanish Science and Innovation Ministry), whose aim is to develop an intelligent chip to regulate diabetes in any kind of patients suffering this disease. With this research, the idea is to extract the interstitial liquid with micro needles that are 200 microns long (the double than a hair"s thickness). This painless process is carried out with sensors and micro fluidics and patients are informed every now and again in their mobiles of their level of glucose. "There are many devices in the glucose field that do work, but the novelty of our research work is that we can use the same technology to extract liquid and to inject it", José Manuel Quero says. He does not hesitate to stress that the following stage would consist of providing insulin almost automatically, and always under medical supervision. This could be also applied to many other medicaments. Prof. Quero points out that during the first of the four years of works, efforts have been focused on solving the different parts the patch is made up of. In the next few months issues regarding the integration of the components, assessment of the results and adjustment will be dealt with. That is why the initial phase of the project consisted of the design of the micro needles. "To put it simple, we have used a biocompatible material, SU8 (photo sensible polymer) which we have processed using different techniques to obtain the needles and be able to put them in a flexible printed circuit (or PCB)" Carmen Aracil Fernández, researcher of the group points out. In order to extract the liquid, we are using a patent of the University of Seville which allows to create a micro syringe made up by a small deposit with a whole linked to the needle which is topped by a membrane that can be destroyed in a control way. Researchers are currently working on the creation of a system able to measure the different variables that determine factors such as the level of glucose. That"s why they are focusing on the design of the Lab on Chip. "The idea is that the liquids we take go through a circuit designed by means of micro fluidics, where the different sensors are mixed with reactive elements, etc" , the head of the project points out. Andalucía Innova


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009